Metastatic Gastric Cancer Clinical Trial
Official title:
Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study
The goal of this phase 2 clinical trial is to evaluate the efficacy of nivolumab in combination with CAPOX in patients with FGFR2-positive/PD-L1-positive/HER2-negative metastatic gastric cancer.
On April 16, 2021, the Food and Drug Administration approved first-line therapy with nivolumab and fluoropyrimidine-platinum-containing chemotherapy for metastatic gastric adenocarcinoma. Patients with PD-L1 expression benefit the most from this treatment. Fibroblast growth factor receptor 2 (FGFR2) is a predictor of poor overall survival and a potential target for targeted therapy. However, there is no data of nivolumab efficacy in patients with combined expression of PD-L1 and FGFR2. The aim of this study is to evaluate the preliminary efficacy of nivolumab in this patient population. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04618809 -
Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer
|
N/A | |
| Recruiting |
NCT02668380 -
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
|
N/A | |
| Completed |
NCT03121807 -
Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer
|
N/A | |
| Recruiting |
NCT04358354 -
Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer
|
Phase 3 | |
| Completed |
NCT01099527 -
A Trial of RAD001/Capecitabine in Refractory Gastric Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00253370 -
Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer
|
Phase 2 | |
| Recruiting |
NCT02002195 -
Modified Folinic Acid-Fluorouracil-Oxaliplatin Regimen + Capecitabine for Elderly With Metastatic Gastric Cancer
|
||
| Recruiting |
NCT06008925 -
Clinical Study of VG161 Combined With Nivolumab Injection in Patients With Advanced Metastatic Gastric Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05714124 -
Liver Embolization Approaches for Tumor Management
|
||
| Recruiting |
NCT02855788 -
Metronomic Chemotherapy in Advanced Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT03154983 -
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT04263870 -
Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction
|
Phase 2 | |
| Active, not recruiting |
NCT01359397 -
Docetaxel, Oxaliplatin, Capecitabine, Bevacizumab and Trastuzumab in Patients With Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04739202 -
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)
|
Phase 2 | |
| Completed |
NCT03409848 -
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma
|
Phase 2 | |
| Recruiting |
NCT05955833 -
89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study
|
Phase 1 | |
| Terminated |
NCT01528501 -
Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008)
|
Phase 2 | |
| Completed |
NCT03751761 -
GC 2nd Line Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel Study
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05024812 -
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03614013 -
Resistance to Immunotherapy in Gastric Cancer
|